Protalix is a biopharmaceutical company that specializes in the manufacture of recombinant therapeutic proteins through its ProCellEx plant cell-based protein expression system. Using ProCellEx, Protalix is developing a proprietary pipeline of biobetter and biosimilar recombinant proteins that target large, established markets and that rely upon known biological mechanisms of action.

biopharmaceuticals
Public (NYSE:PLX)
Visit Website
Additional Portfolio Companies
ABAC Therapeutics
Adicet Bio
ArQule
Cathworks
Dynacure
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Horama
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Ocon Medical
Prevail Therapeutics
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
June 26, 2015